Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity lowers IG Group to 'hold'

(Sharecast News) - Analysts at Canaccord Genuity downgraded online trading platform operator IG Group from 'buy' to 'hold' on Friday as a result of the company issued "a positive trading update" and "instigated some changes" to its capital structure over the last few weeks. The Canadian bank noted that IG's trading update on 12 May said "the business has performed strongly in Q425" and that it now expects FY results to be ahead of consensus. It also highlighted that IG's Freetrade acquisition, completed on 1 April, was said to have traded well in Q425, with its performance being in line with management's expectations.

Additionally, Canaccord noted that IG refinanced its £400.0m revolving credit facility, due to mature in October 2026, with a £600.0m facility, maturing in May 2030 and pointed out that on 22 May, IG issued £250.0m of fixed rate notes, with a maturity date of 22 October 2030.

Canaccord said that its assumption was that "meaningful spikes in market volatility", a key driver of new client acquisition and trading activity, were infrequent and impossible to forecast and therefore, tried to model more normalised trading conditions, outside of macro and market shocks relevant to its forecast assumptions and horizon. Consequently, after what Canaccord considers to be the short-term boost provided by recent volatility, it expects adjusted earnings per share to decline by 16% year-on-year in FY27.

"We believe investors should consider buying IGG when volatility is low, not at a cyclical high as it has been in recent weeks. This characteristic, coupled with the underlying growth challenge referenced above, talks against us being more positive on the stock at this point," said Canaccord, which did hike its price target on the stock from 782.0p to 1,099.0p.

"We are conscious that the current strategy appears to be focused on increased dividends, further buybacks and possible M&A. This could provide share price support but seems unlikely to deliver strong, sustainable EPS growth."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.